Scientific work

Uzm. Dr. Gündüzalp Buğrahan Babacan

21 publications. The source of the information is stated next to each publication.

Back to profile

  1. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Open-access full textSource: OpenAlex

  2. Diffuse Gastric Uptake and Metabolic Superscan in the Patient with Multiple Myeloma

    Molecular imaging and radionuclide therapy, 2026

    DOI 10.4274/mirt.galenos.2026.43765 PMID 42334005 Open-access full textSource: Europe PMC

  3. Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

    Diagnostics, 2026

    DOI 10.3390/diagnostics16203359 PMID 42938199 Open-access full textSource: ORCID

  4. Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2025.500112 PMID 39921170 Source: ORCID

  5. Nuevo método de heterogeneidad para predecir la supervivencia en el cáncer de mama triple negativo no metastásico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2025.500112 Source: ORCID

  6. The effect of digital PET/CT and reconstruction algorithms on semi-quantitative values and Deauville scoring in patients with lymphoma.

    PubMed, 2025

    DOI 10.1967/s002449912904 PMID 41389257 Source: OpenAlex

  7. Comparison of different response evaluation criteria in interim PET/CT for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?

    Nuclear Medicine Communications, 2025

    DOI 10.1097/mnm.0000000000002047 PMID 40910350 Source: ORCID

  8. Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500080 Source: ORCID

  9. Utilidad de la PET/TC con [18F]FDG más allá de la estadificación: importancia pronóstica de la sarcopenia y del metabolismo del tejido adiposo en el carcinoma esofágico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500090 Source: ORCID

  10. [18F]FDG PET/CT beyond staging: Prognostic significance of sarcopenia and adipose tissue metabolism in esophageal carcinomas

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2024.500090 PMID 39732336 Source: ORCID

  11. Is There Novel 18F-FDG Biodistribution in the Digital PET/CT Era? A Real-World Data Analysis

    Cancer Biotherapy and Radiopharmaceuticals, 2025

    DOI 10.1089/cbr.2024.0226 PMID 39866138 Source: ORCID

  12. Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective

    Turkish journal of medical sciences, 2025

    DOI 10.55730/1300-0144.5944 PMID 40104288 2 citations (Europe PMC) Open-access full textSource: Europe PMC

  13. Evaluating the correlation between pretreatment 18F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival

    Pathology & Oncology Research, 2025

    DOI 10.3389/pore.2024.1612014 PMID 39839836 5 citations (OpenAlex) Open-access full textSource: OpenAlex

  14. Unusual Presence of Synchronous Primary Ovarian and Thyroid Extranodal Non-Hodgkin Lymphoma Without Lymph Node Involvement

    Clinical Nuclear Medicine, 2024

    DOI 10.1097/rlu.0000000000005108 PMID 38350088 2 citations (OpenAlex) Source: OpenAlex

  15. The effect of reconstruction algorithms on semi-quantitative measurements in 18F-FDG PET/CT imaging.

    PubMed, 2024

    DOI 10.1967/s002449912721 PMID 39097805 2 citations (OpenAlex) Source: OpenAlex

  16. The relationship between HER2 status acquired from pathological data and metabolic parameters from pre-treatment [18F]FDG PET/CT in gastric adenocarcinomas

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2024

    DOI 10.1016/j.remnie.2024.500080 PMID 39710040 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  17. Follicular Thyroid Carcinoma with Unusual Mandible Metastasis

    Indian Journal of Nuclear Medicine, 2024

    DOI 10.4103/ijnm.ijnm_6_24 PMID 38989304 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  18. Comparison of the 68Ga-FAPI Versus 18F-FDG in Gastric Adenocarcinoma and Anthracosis-Associated Lymph Nodes: FAPI Unmasking False-Negatives and False-Positives

    Clinical Nuclear Medicine, 2024

    DOI 10.1097/rlu.0000000000005026 PMID 38271247 2 citations (OpenAlex) Source: OpenAlex

  19. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer

    Molecular imaging and radionuclide therapy, 2023

    DOI 10.4274/mirt.galenos.2022.05826 PMID 37337764 4 citations (Europe PMC) Open-access full textSource: Europe PMC

  20. Unusual spread of the follicular thyroid carcinoma, metastases to liver and pancreas

    Médecine Nucléaire, 2023

    DOI 10.1016/j.mednuc.2023.03.010 Source: ORCID

  21. Meningioma Mimicking Bone Metastasis in Breast Cancer

    Molecular Imaging and Radionuclide Therapy, 2023

    DOI 10.4274/mirt.galenos.2022.31032 PMID 37337873 Open-access full textSource: ORCID